Many new medicines that work directly on the body’s immune system are being studied for the treatment of COPD. In 2024, Dupixent became the first of these medicines to be approved for COPD.

Fact checked by Jennifer Klump Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD ...

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with ...

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with ...

The FDA cleared Dupixent for people with COPD who are also using inhaled COPD medications yet still have too many eosinophils. An important part of the immune system, eosinophils are a type of ...

European approval of Dupixent is the second approval of a COPD drug in the span of a week. On June 26, Verona Pharma won FDA approval of Ohtuvayre, an inhaled drug that inhibits the enzymes PDE-3 ...

Dupixent is an antibody designed to block IL-13 and IL-4, two signaling pathways that drive inflammation. In COPD, the drug is intended to specifically address type 2 inflammation, an excessive ...

Dupixent ® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious ...

Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious ...